The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
News & Analysis: Cellectis
Despite getting passed along to a biotech start-up, Cellectis could have a bright future.
Belldegrun's Allogene Therapeutics has just inked a transformative deal to land Pfizer's CAR-T cancer gene therapy program.
Find out why these stocks missed out on the rally.
On a day when markets in general headed lower on macro-level fears, these shares lead the way down due to more company-specific issues.
The biopharma became the latest in the CAR-T space to receive a clinical hold from the FDA.
Gene editing appears poised to usher in a brave new world for biotech.
Here are four stocks we're watching closely.
Acceleron Pharma, Cellectis SA, and Amicus Therapeutics' shares are surging higher during the past four weeks.